The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
FTY720, a Novel Immunosuppressant, Induces Sequestration of Circulating Mature Lymphocytes by Acceleration of Lymphocyte Homing in Rats. I. FTY720 Selectively Decreases the Number of Circulating Mature Lymphocytes by Acceleration of Lymphocyte Homing
Abstract
FTY720, given i.v. or orally at 0.03 mg/kg or more, significantly prolonged skin allograft survival in a dose-dependent manner and showed more potent immunosuppressive activity than cyclosporin A (CsA) or tacrolimus (FK506) in MHC-incompatible rat strains of WKAH donors and F344 recipients. However, unlike CsA or FK506, FTY720 up to 1000 nM did not affect IL-2 production in allogeneic MLC. Within 3 to 24 h after a single oral administration of FTY720 at 0.1 to 1 mg/kg, the number of lymphocytes in the rats was markedly decreased in the peripheral blood and thoracic duct lymph and partially in spleen. By contrast, the number of lymphocytes in peripheral lymph nodes (PLN), mesenteric lymph nodes (MLN), and Peyer’s patches (PP) was significantly increased at the same time. Intravenous transfusion of calcein-labeled rat lymphocytes into rats revealed that FTY720 significantly accelerated lymphocyte homing to PLN, MLN, and PP, dose dependently. Since FTY720-induced lymphocyte homing was completely blocked by simultaneous treatment of the calcein-labeled lymphocytes with mAbs against CD62L, CD49d, and CD11a before the transfusion, the acceleration of lymphocyte homing by FTY720 appears to be mediated by lymphocyte-homing receptors. These findings indicate that FTY720 sequesters circulating mature lymphocytes into PLN, MLN, and PP by acceleration of lymphocyte homing and thereby decreases the number of lymphocytes in peripheral blood, thoracic duct lymph, and spleen. Based on these observations, sequestration of circulating mature-lymphocytes is presumed to be a main mechanism of the immunosuppressive activity of FTY720.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes
Liu, J., Farmer, J. D., Lane, W. S., Friedman, J., Weissman, I., & Schreiber, S. L. (1991) · Cell · doi:10.1016/0092-8674(91)90124-h · Cited by 4,116 · cited 1×
“Although CsA and FK506 bind to different proteins, cyclophilin and FK506 binding protein (FKBP), respectively, both cyclophilin/CsA and FKBP/FK506 complexes inhibit the phosphatase activity of calcineurin, which activates NF-AT involved in the promotion of IL-2 gene transcription (6).”
BackgroundT Cell Growth Factor: Parameters of Production and a Quantitative Microassay for Activity
Gillis, S., Ferm, M. M., Ou, W., & Smith, K. A. (1978) · The Journal of Immunology · doi:10.4049/jimmunol.120.6.2027 · Cited by 3,273
Lymphocyte Homing and Homeostasis
Butcher, E. C., & Picker, L. J. (1996) · Science · doi:10.1126/science.272.5258.60 · Cited by 2,846
A cell-surface molecule involved in organ-specific homing of lymphocytes
Gallatin, W. M., Weissman, I. L., & Butcher, E. C. (1983) · Nature · doi:10.1038/304030a0 · Cited by 1,484
α4β7 integrin mediates lymphocyte binding to the mucosal vascular addressin MAdCAM-1
Berlin, C., Berg, E. L., Briskin, M. J., Andrew, D. P., Kilshaw, P. J., Holzmann, B., Weissman, I. L., Hamann, A., & Butcher, E. C. (1993) · Cell · doi:10.1016/0092-8674(93)90305-a · Cited by 1,453
KINO, T., HATANAKA, H., MIYATA, S., INAMURA, N., NISHIYAMA, M., YAJIMA, T., GOTO, T., OKUHARA, M., KOHSAKA, M., AOKI, H., et al. (1987) · The Journal of Antibiotics · doi:10.7164/antibiotics.40.1256 · Cited by 1,209
CYCLOSPORIN A IN PATIENTS RECEIVING RENAL ALLOGRAFTS FROM CADAVER DONORS
Calne, R. Y., Thiru, S., Mcmaster, P., Craddock, G. N., White, D. J. G., Evans, D. B., Dunn, D. C., Pentlow, B. D., & Rolles, K. (1978) · The Lancet · doi:10.1016/s0140-6736(78)91970-0 · Cited by 1,002
T-cell adhesion induced by proteoglycan-immobilized cytokine MIP-lβ
Tanaka, Y., Adams, D. H., Hubscher, S., Hirano, H., Siebenlist, U., & Shaw, S. (1993) · Nature · doi:10.1038/361079a0 · Cited by 873
Lymphocyte homing and leukocyte rolling and migration are impaired in L-selectin-deficient mice
Arbonés, M. L., Ord, D. C., Ley, K., Ratech, H., Maynard-Curry, C., Otten, G., Capon, D. J., & Teddert, T. F. (1994) · Immunity · doi:10.1016/1074-7613(94)90076-0 · Cited by 831
(1994) · The Lancet · doi:10.1016/s0140-6736(94)91766-3 · Cited by 656
Cited by
Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1
Matloubian, M., Lo, C. G., Cinamon, G., Lesneski, M. J., Xu, Y., Brinkmann, V., Allende, M. L., Proia, R. L., & Cyster, J. G. (2004) · Nature · doi:10.1038/nature02284 · Cited by 2,581
Alteration of Lymphocyte Trafficking by Sphingosine-1-Phosphate Receptor Agonists
Mandala, S., Hajdu, R., Bergstrom, J., Quackenbush, E., Xie, J., Milligan, J., Thornton, R., Shei, G.-J., Card, D., Keohane, C., et al. (2002) · Science · doi:10.1126/science.1070238 · Cited by 1,690
The Immune Modulator FTY720 Targets Sphingosine 1-Phosphate Receptors
Brinkmann, V., Davis, M. D., Heise, C. E., Albert, R., Cottens, S., Hof, R., Bruns, C., Prieschl, E., Baumruker, T., Hiestand, P., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.c200176200 · Cited by 1,504
Homing and cellular traffic in lymph nodes
von Andrian, U. H., & Mempel, T. R. (2003) · Nature Reviews Immunology · doi:10.1038/nri1222 · Cited by 1,281
Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis
Brinkmann, V., Billich, A., Baumruker, T., Heining, P., Schmouder, R., Francis, G., Aradhye, S., & Burtin, P. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3248 · Cited by 1,273
Chemokines, sphingosine-1-phosphate, and cell migration in secondary lymphoid organs
Cyster, J. G. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115628 · Cited by 856
Massberg, S., Schaerli, P., Knezevic-Maramica, I., Köllnberger, M., Tubo, N., Moseman, E. A., Huff, I. V., Junt, T., Wagers, A. J., Mazo, I. B., et al. (2007) · Cell · doi:10.1016/j.cell.2007.09.047 · Cited by 696
Unleashing Type-2 Dendritic Cells to Drive Protective Antitumor CD4+ T Cell Immunity
Binnewies, M., Mujal, A. M., Pollack, J. L., Combes, A. J., Hardison, E. A., Barry, K. C., Tsui, J., Ruhland, M. K., Kersten, K., Abushawish, M. A., et al. (2019) · Cell · doi:10.1016/j.cell.2019.02.005 · Cited by 629
Finding a way out: lymphocyte egress from lymphoid organs
Schwab, S. R., & Cyster, J. G. (2007) · Nature Immunology · doi:10.1038/ni1545 · Cited by 605
The immunosuppressant FTY720 down‐regulates sphingosine 1‐phosphate G protein‐coupled receptors
Gräler, M. H., & Goetzl, E. J. (2004) · The FASEB Journal · doi:10.1096/fj.03-0910fje · Cited by 539
Immunobiology of Allogeneic Hematopoietic Stem Cell Transplantation
Welniak, L. A., Blazar, B. R., & Murphy, W. J. (2007) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141606 · Cited by 520
Brinkmann, V., Cyster, J. G., & Hla, T. (2004) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2004.00476.x · Cited by 478
Fluorescent dyes for lymphocyte migration and proliferation studies
Parish, C. R. (1999) · Immunology & Cell Biology · doi:10.1046/j.1440-1711.1999.00877.x · Cited by 473
Expression of the Sphingosine 1-Phosphate Receptor, S1P1, on T-cells Controls Thymic Emigration
Allende, M. L., Dreier, J. L., Mandala, S., & Proia, R. L. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m314291200 · Cited by 452
Mice Deficient in Sphingosine Kinase 1 Are Rendered Lymphopenic by FTY720
Allende, M. L., Sasaki, T., Kawai, H., Olivera, A., Mi, Y., van Echten-Deckert, G., Hajdu, R., Rosenbach, M., Keohane, C. A., Mandala, S., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m406512200 · Cited by 447
Phosphorylation of the immunomodulatory drug FTY720 by sphingosine kinases
Billich, A., Bornancin, F., Dévay, P., Mechtcheriakova, D., Urtz, N., & Baumruker, T. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m307687200 · Cited by 433
Sphingosine 1-phosphate receptor 1 promotes B cell localization in the splenic marginal zone
Cinamon, G., Matloubian, M., Lesneski, M. J., Xu, Y., Low, C., Lu, T., Proia, R. L., & Cyster, J. G. (2004) · Nature Immunology · doi:10.1038/ni1083 · Cited by 418
Tomura, M., Yoshida, N., Tanaka, J., Karasawa, S., Miwa, Y., Miyawaki, A., & Kanagawa, O. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0802278105 · Cited by 413
Sphingosine 1-Phosphate Receptor Signaling
Rosen, H., Gonzalez-Cabrera, P. J., Sanna, M. G., & Brown, S. (2009) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.78.072407.103733 · Cited by 404
Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis
Cohen, J. A., & Chun, J. (2011) · Annals of Neurology · doi:10.1002/ana.22426 · Cited by 393
Persistent signaling induced by FTY720-phosphate is mediated by internalized S1P1 receptors
Mullershausen, F., Zecri, F., Cetin, C., Billich, A., Guerini, D., & Seuwen, K. (2009) · Nature Chemical Biology · doi:10.1038/nchembio.173 · Cited by 370
Pinschewer, D. D., Ochsenbein, A. F., Odermatt, B., Brinkmann, V., Hengartner, H., & Zinkernagel, R. M. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.11.5761 · Cited by 365
An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis
Garg, N., & Smith, T. W. (2015) · Brain and Behavior · doi:10.1002/brb3.362 · Cited by 348
Forrest, M., Sun, S.-Y., Hajdu, R., Bergstrom, J., Card, D., Doherty, G., Hale, J., Keohane, C., Meyers, C., Milligan, J., et al. (2004) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.062828 · Cited by 333
Chiba, K. (2005) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.05.002 · Cited by 321
Self-citationLo, C. G., Xu, Y., Proia, R. L., & Cyster, J. G. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20041509 · Cited by 319
Kurobe, H., Liu, C., Ueno, T., Saito, F., Ohigashi, I., Seach, N., Arakaki, R., Hayashi, Y., Kitagawa, T., Lipp, M., et al. (2006) · Immunity · doi:10.1016/j.immuni.2005.12.011 · Cited by 311
Amelioration of Experimental Autoimmune Encephalomyelitis in Lewis Rats by FTY720 Treatment
Fujino, M., Funeshima, N., Kitazawa, Y., Kimura, H., Amemiya, H., Suzuki, S., & Li, X.-K. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.045658 · Cited by 280
Sphingosine Kinase: Biochemical and Cellular Regulation and Role in Disease
Taha, T. A., Hannun, Y. A., & Obeid, L. M. (2006) · BMB Reports · doi:10.5483/bmbrep.2006.39.2.113 · Cited by 276
First Human Trial of FTY720, a Novel Immunomodulator, in Stable Renal Transplant Patients
Budde, K., Schmouder, R. L., Brunkhorst, R., Nashan, B., Lu[Combining Diaeresis]cker, P. W., Mayer, T., Choudhury, S., Skerjanec, A., Kraus, G., & Neumayer, H. H. (2002) · Journal of the American Society of Nephrology · doi:10.1681/asn.v1341073 · Cited by 270
Sphingosine 1-Phosphate Analogs as Receptor Antagonists
Davis, M. D., Clemens, J. J., Macdonald, T. L., & Lynch, K. R. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m412356200 · Cited by 269
Sphingosine 1-phosphate and inflammation
Obinata, H., & Hla, T. (2019) · International Immunology · doi:10.1093/intimm/dxz037 · Cited by 268
Sphingosine kinase type 2 is essential for lymphopenia induced by the immunomodulatory drug FTY720
Zemann, B., Kinzel, B., Müller, M., Reuschel, R., Mechtcheriakova, D., Urtz, N., Bornancin, F., Baumruker, T., & Billich, A. (2006) · Blood · doi:10.1182/blood-2005-07-2628 · Cited by 264
Brinkmann, V., & Lynch, K. R. (2002) · Current Opinion in Immunology · doi:10.1016/s0952-7915(02)00374-6 · Cited by 262
Yanagawa, Y., Sugahara, K., Kataoka, H., Kawaguchi, T., Masubuchi, Y., & Chiba, K. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.160.11.5493 · Cited by 260
Self-citationIndustrial natural product chemistry for drug discovery and development
Bauer, A., & Brönstrup, M. (2014) · Nat. Prod. Rep. · doi:10.1039/c3np70058e · Cited by 255
Chun, J., Kihara, Y., Jonnalagadda, D., & Blaho, V. A. (2019) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010818-021358 · Cited by 131
“A key effect of fingolimod in MS is its reduction of peripheral blood lymphocytes, particularly T cell subtypes, which had been observed both in early preclinical studies (85, 103, 104, 113) and in clinical trials (1, 5, 6, 130).”
BackgroundMethodInfluentialFinding a way out: S1P signaling and immune cell migration
Baeyens, A. A. L., & Schwab, S. R. (2020) · Annual Review of Immunology · doi:10.1146/annurev-immunol-081519-083952 · Cited by 123
Copland, D. A., Liu, J., Schewitz-Bowers, L. P., Brinkmann, V., Anderson, K., Nicholson, L. B., & Dick, A. D. (2012) · The American Journal of Pathology · doi:10.1016/j.ajpath.2011.10.008 · Cited by 50
Fingolimod (FTY720) as an acute rescue therapy for intraocular inflammatory disease
Raveney, B. J. E., Copland, D. A., Nicholson, L. B., & Dick, A. D. (2008) · Archives of Ophthalmology · doi:10.1001/archopht.126.10.1390 · Cited by 39
Tsuji, T., Okuno, S., Kuroda, A., Hamazaki, J., Chikami, T., Sakurai, S., Yoshida, Y., Banno, R., Fujita, T., & Kohno, T. (2016) · Allergology International · doi:10.1016/j.alit.2015.10.009 · Cited by 8
Metadata
- Authors
- Chiba, K., Yanagawa, Y., Masubuchi, Y., Kataoka, H., Kawaguchi, T., Ohtsuki, M., & Hoshino, Y.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 1998-05
- Volume
- 160
- Issue
- 10
- Pages
- 5037-5044
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W1949682302
- Cited by
- 596
- References
- 36
- FWCI
- 7.09
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.